New Pain Drug Boosts Effects of Opioids

Patients taking the new drug will experience a more robust analgesic effect, will need smaller doses of opioids, and have fewer side effects and less tolerance. The new technology was developed by TheraQuest Biosciences (Blue Bell, PA, USA).

"Results from our experiments in preclinical models of pain demonstrate that TQ-1016 increases the potency of morphine 300-400%,” noted Najib Babul, PharmD., president and CEO of TherapQuest. "If the results are confirmed in phase II clinical trials, this discovery could be commercially exploited to yield a number of analgesic combinations with better efficacy and tolerability and reduced narcotic tolerance.”

TheraQuest is a pain-management company, engaged in developing new candidates for treating pain that have lower development costs and reduced regulatory risk.




Related Links:
TheraQuest